Ignite Creation Date:
2024-05-05 @ 11:53 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00163085
Status:
COMPLETED
Last Update Posted:
2006-09-22
First Post:
2005-09-09
Brief Title:
The Effects of an NR2B NMDA Antagonist CP-101606 in Patients With Parkinsons Disease
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Crossover Study To Explore The Efficacy And Safety Of The NR2B NMDA Antagonist CP-101606 In Patients With Idiopathic Parkinsons Disease
Status:
COMPLETED
Status Verified Date:
2006-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine the effects of the NMDA antagonist CP-101606 in subjects with Parkinsons Disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None